论文部分内容阅读
目的评价美托洛尔治疗老年人慢性心力衰竭(CHF)的疗效及安全性。方法 79例老年人CHF患者随机分为两组,治疗组40例在常规抗心力衰竭治疗基础上加用美托洛尔6.25～50mg、bid;对照组39例采用常规抗心力衰竭治疗,未用美托洛尔。定期随访观察临床表现,监测治疗前后心率、血压及心功能参数变化。结果治疗组显效率52.5%、总有效率87.5%,对照组显效率35.9%、总有效率66.7%,两者比较有显著性差异(P<0.05),治疗组患者心率减慢、血压降低较对照组明显,超声心动图复查显示治疗6月后左室舒张末期内径缩小,左室射血分数增高较对照组显著。结论美托洛尔对老年人CHF是一种较为安全有效的药物。
Objective To evaluate the efficacy and safety of metoprolol in the treatment of elderly patients with chronic heart failure (CHF). Methods A total of 79 elderly CHF patients were randomly divided into two groups. Forty patients in the treatment group received metoprolol 6.25-50 mg bid on the basis of routine anti-heart failure treatment, and 39 patients in the control group received conventional anti-heart failure treatment. Metoprolol. Regular follow-up observation of clinical manifestations, monitoring heart rate, blood pressure and heart function parameters before and after treatment. Results The effective rate of the treatment group was 52.5%, the total effective rate was 87.5%, the effective rate of the control group was 35.9% and the total effective rate was 66.7%. There was significant difference between the two groups (P <0.05). The treatment group had slower heart rate and lower blood pressure Control group significantly, echocardiography review showed that after 6 months of treatment left ventricular end-diastolic diameter narrowed, left ventricular ejection fraction increased significantly than the control group. Conclusion Metoprolol is a safe and effective drug for CHF in the elderly.